Table 1.
Correlation between miR-602 Expression and Clinicopathological Parameters of ESCC Patients
| Characteristic | Discovery Group (n = 93) |
Validation Group (n = 108) |
||||
|---|---|---|---|---|---|---|
| Low (n = 19) | High (n = 74) | p Value | Low (n = 31) | High (n = 77) | p Value | |
| Gender | ||||||
| Male | 15 (19.5%) | 62 (80.5%) | 0.618 |
24 (26.7%) | 66 (73.3%) | 0.295 |
| Female | 4 (25.0%) | 12 (75.0%) | 7 (38.9%) | 11 (61.1%) | ||
| Age (Years) | ||||||
| ≤60 | 6 (22.2%) | 21 (77.8%) | 0.784 |
8 (21.1%) | 30 (78.9%) | 0.195 |
| >60 | 13 (19.7%) | 53 (80.3%) | 23 (32.9%) | 47 (67.1%) | ||
| Tumor Size (cm) | ||||||
| <5 | 10 (19.6%) | 41 (80.4%) | 0.828 |
18 (25.7%) | 52 (74.3%) | 0.351 |
| ≥5 | 9 (21.4%) | 33 (78.6%) | 13 (34.2%) | 25 (65.8%) | ||
| Tumor Stagea | ||||||
| T1 + T2 | 7 (31.8%) | 15 (68.2%) | 0.146 |
8 (30.8%) | 18 (69.2%) | 0.789 |
| T3 + T4 | 11 (17.2%) | 53 (82.8%) | 23 (28.0%) | 59 (72.0%) | ||
| Histological Grade | ||||||
| Well and moderate | 16 (21.6%) | 58 (78.4%) | 0.574 |
24 (27.3%) | 64 (72.7%) | 0.490 |
| Poor and NS | 3 (15.8%) | 16 (84.2%) | 7 (35.0%) | 13 (65.0%) | ||
| Lymph Node Metastasis | ||||||
| Negative | 15 (33.3%) | 30 (66.7%) | 0.003 |
26 (43.3%) | 34 (56.7%) | 0.000 |
| Positive | 4 (8.3%) | 44 (91.7%) | 5 (10.4%) | 43 (89.6%) | ||
| Clinical Stagea | ||||||
| I + II | 15 (31.2%) | 33 (68.8%) | 0.006 | 25 (41.7%) | 35 (58.3%) | 0.001 |
| III + IV | 3 (7.5%) | 37 (92.5%) | 6 (12.5%) | 43 (87.5%) | ||
a
Numbers do not equal to the total number due to missing data.